Dr. Saag has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) from Roche, BMS, and Amgen.
Tumor Necrosis Factor, Tuberculosis, Testing, and Treatment: Teeing Up the Questions
Version of Record online: 28 OCT 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 11, pages 1719–1721, November 2013
How to Cite
Saag, K. G., Winthrop, K. and Curtis, J. R. (2013), Tumor Necrosis Factor, Tuberculosis, Testing, and Treatment: Teeing Up the Questions. Arthritis Care Res, 65: 1719–1721. doi: 10.1002/acr.22061
- Issue online: 28 OCT 2013
- Version of Record online: 28 OCT 2013
- Accepted manuscript online: 8 JUL 2013 09:27AM EST
- Manuscript Accepted: 8 JUN 2013
- Manuscript Received: 14 MAY 2013
- 2Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.MMWR Recomm Rep2000;49:1–51.
- 4Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry.Arthritis Rheum2009;60:1884–94., , , , , , et al.